Overview

Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the long-term safety of teriflunomide in multiple sclerosis subjects. The secondary objective is to assess the long-term efficacy.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi
Treatments:
Teriflunomide